# Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis

> **NCT05354674** · — · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 302 (estimated)

## Conditions studied

- Colorectal Cancer
- Liver Metastases

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05354674
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2025-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 302 (ESTIMATED)
- **Last updated:** 2023-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05354674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05354674, "Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05354674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*